ArticleThe Pediatric infectious disease journal2026
Evaluation of Rotavirus Vaccine Effectiveness by Severity of Rotavirus Disease: Findings From the MNSSTER-V Project.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
backgroundSince the introduction of rotavirus vaccines, acute gastroenteritis (AGE) hospitalizations due to rotavirus have decreased globally; however, vaccine effectiveness (VE) differs by country, age and disease severity. We evaluated rotavirus VE by disease severity in different age groups and under-5 childhood mortality (U5M) strata.
methodsThe Vesikari score is a common measure of AGE disease severity. A modified Vesikari Score (mVS) was calculated for 18,426 children with medically attended AGE across 16 countries from the Multi-National Subpopulations Study To Evaluate Rotavirus Vaccines dataset. Using a test-negative case-control design (cases had rotavirus-positive AGE and controls had rotavirus-negative AGE), we calculated complete rotavirus series VE against different severity categories among children 6-59 months old, stratified by age and country U5M level, respectively.
resultsVE increased with increasing disease severity: 38% (95% confidence interval [CI]:17-53) for mild/moderate disease versus 58% (95% CI: 50-64) for severe/very severe disease, and this pattern persisted with stratification by age and U5M. Among children with severe/very severe disease, VE was higher in infants aged 6-11 months (62%, 95% CI: 51-70) compared with children aged 24-59 months (11%, 95% CI: -78 to 56), and lower among children in the highest U5M strata (44%, 95% CI: 26-58) compared to children in the high U5M strata (60%, 95% CI: 47-69).
conclusionsRotavirus vaccines provide the greatest protection against very severe rotavirus disease. VE remains lower in countries with higher U5M levels, even among children with very severe rotavirus disease, highlighting the need for improved vaccine performance in countries with high disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.